A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AXEPT
- 01 Nov 2021 the results of a preplanned analysis of the AXEPT study that evaluated the associations between the UGT1A1 genotype and the safety and efficacy of irinotecan-based regimens published in the Cancer Science
- 31 May 2020 Results of post-hoc analysis presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 19 Jan 2019 Results (n=642) presented at the 2019 Gastrointestinal Cancers Symposium.